We have comprehensively supplied a profound understanding of the overall molecular changes in the pathological mechanism of PM/DM and recognized five hub genes as potential therapeutic targets, including TRIM22, IFI6, IFITM1, IFI35, and IRF9. This evidence concerns the gene TRIM22 and polymyositis.